Oncology is the branch of medicine that deals with the study, diagnosis and treatment of cancer and focuses on the management of cancer from diagnosis through to palliative care.
Cancer is a group of cells (usually derived from a single cell) that has lost its normal control mechanisms. Cancerous cells can develop from any tissue within any organ and can spread throughout the body (metastasise). Cancerous tissue can be divided into those of the blood and blood-forming tissue, and solid tumours, carcinomas or sarcomas, or described as breast cancer including metastatic breast cancer, HER2+, triple negative, gynaecological cancers such as ovarian and cervical, and genitourinary cancer such as prostate cancer.
Related news and insights
AstraZeneca and Daiichi Sankyo have announced that the FDA has approved label expansion for Enhertu (fam-trastuzumab deruxtecan-nxki) to include adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma that would have previously been treated with a trastuzumab-based regimen.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
BeiGene, Ltd. announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC).
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy.
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected.